financetom
Business
financetom
/
Business
/
Trump says JPMorgan's Dimon won't be invited to join his administration
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Trump says JPMorgan's Dimon won't be invited to join his administration
Nov 15, 2024 11:56 AM

WASHINGTON, Nov 14 (Reuters) - JPMorgan Chase ( JPM )

CEO Jamie Dimon will not be invited to be a part of Donald

Trump's administration, the U.S. president-elect said on social

media on Thursday.

"I respect Jamie Dimon, of JPMorgan Chase ( JPM ), greatly, but he

will not be invited to be a part of the Trump Administration,"

Trump said in his post.

A source told Reuters last week Dimon will remain at the

bank and had no plans to join Trump's administration after

earlier having been the subject of speculation as a Treasury

secretary candidate in the run-up to the Nov. 5 election.

Trump, a Republican, beat Democratic Vice President

Kamala Harris in the election. Dimon said last month that his

chances of taking an official post were "almost nil".

Trump is yet to announce a Treasury secretary pick.

Billionaire banker Howard Lutnick and investor Scott Bessent are

the

top contenders

for the role, sources have told Reuters.

Dimon, who is one of the most prominent leaders in

corporate America, has run JPMorgan ( JPM ) for almost 19 years.

Dimon and other members of the bank's operating

committee congratulated Trump and other elected representatives,

according to a memo to staff last week seen by Reuters.

The outspoken CEO travels frequently to Washington to

speak with policymakers and has expressed views on everything

from housing and the U.S.-China relationship to the economy. He

continued his tradition of not endorsing any presidential

candidate this year.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Castle Biosciences Says FDA Granted Breakthrough Device Designation to Skin Cancer Test; Shares Up Pre-Bell
Castle Biosciences Says FDA Granted Breakthrough Device Designation to Skin Cancer Test; Shares Up Pre-Bell
Jul 23, 2025
07:31 AM EDT, 07/23/2025 (MT Newswires) -- Castle Biosciences ( CSTL ) said Wednesday the US Food and Drug Administration has granted breakthrough device designation for the company's DecisionDx-Melanoma test. DecisionDx-Melanoma is a gene expression profile test that provides results to guide risk-aligned management decisions for patients diagnosed with stage I to III cutaneous melanoma, a type of skin cancer....
Healthcare Services Q2 Loss Widens, Revenue Rises
Healthcare Services Q2 Loss Widens, Revenue Rises
Jul 23, 2025
07:34 AM EDT, 07/23/2025 (MT Newswires) -- Healthcare Services Group ( HCSG ) reported a Q2 loss Wednesday of $0.44 per diluted share, wider than a loss of $0.02 a year earlier. Two analysts surveyed by FactSet expected earnings of $0.21 per share. Revenue for the three months ended June 30 was $458.5 million, up from $426.3 million last year....
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Abivax Stock Skyrockets On Strong Data From Inflammatory Bowel Disorder Study
Abivax Stock Skyrockets On Strong Data From Inflammatory Bowel Disorder Study
Jul 23, 2025
Abivax SA ( ABVX ) stock is skyrocketing on Wednesday after the clinical-stage biotechnology company announced overwhelmingly positive topline results from its Phase 3 ABTECT-1 (Study 105) and ABTECT-2 (Study 106) 8-week induction trials for oral obefazimod (ABX464) in adult patients with moderately to severely active ulcerative colitis. The Paris-based company achieved a significant breakthrough with its experimental treatment, which...
Copyright 2023-2026 - www.financetom.com All Rights Reserved